Randy Joe Maddux

Randy Joe Maddux (senior executive) discloses dealings in 2 companies, chiefly Aptevo Therapeutics Inc. and iBio, Inc. We count 6 filings; the first trade dates from 15 November 2017 and the latest from 7 December 2021.

On the open market, the record shows 4 purchases worth €99k and 1 sale worth €23k. Netting one side against the other leaves €77k of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant. In 2022 alone, the filings show no purchases and 1 sale.

A typical purchase (the median) is worth €15k. Clusters matter here: 3 out of 4 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 14 March 2022 with an open-market sale (€23k) in iBio, Inc. The latest purchase dates back some time: it was published 2,638 days ago, on 19 August 2019. Filings reach the SEC (Form 4) feed a median of 5 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.